Recombinant Human Flt-3/Flk-2 Fc Chimera Avi-tag Protein, CF

Recombinant Human Flt-3/Flk-2 Fc Chimera Avi-tag Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: Flt-3/Flk-2

FMS-like tyrosine kinase 3 (Flt‑3), also named Fetal liver kinase-2 (Flk-2) is a member of the class III receptor tyrosine kinase subfamily and plays a role in normal hematopoiesis. The classs III RTK family, which includes Flt-3, KIT, SCFR and CSF1R share a conserved architecture of an extracellular domain (ECD) with five immunoglobulin-like domains, a transmembrane domain and an intracellular region with a juxtamembrane domain and two intracellular tyrosine-kinase domains. The ECD of human Flt-3 shares 85% amino acid sequence identity with mouse Flt-3. Flt-3 expression has been detected in various tissues, including placenta, gonads, and tissues of nervous and hematopoietic origin (1). Among hematopoietic cells, the expression of Flt-3 was found to be restricted to the highly enriched stem/progenitor cell populations (2). The ligand for Flt-3 has been identified as Flt-3 ligand (Flt-3L or FL) and activation of Flt-3 signaling mediates cell survival, cell proliferation, and differentiation of hematopoietic progenitor cells (1). Flt-3 has been implicated in several diseases, including autoimmune diseases, such as rheumatoid arthritis, as well as in acute myeloid leukemia where around one-third of patients carry a Flt-3 mutation which drives the disease and is correlated with poor prognosis (3-5). Our Avi-tag Biotinylated Flt‑3 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

Manufacturing Specifications

1. Kazi, J.U. and Rönnstrand, L. (2019) Physiol Rev. 99:1433.
2. Matthews, W. et al. (1991) Cell 65:1143.
3. Drexler, H.G. (1996) Leukemia 10:588.
4. Grafone, T. et al. (2012) Oncol Rev. 6:e8.
5. Stirewalt, D. and Radich, J. (2003) Nat. Rev. Cancer 3:650.

Related Research Areas

• Acute Myeloid Leukemia
• B Cell Markers
• Dendritic Cell Development
• Hematopoietic Progenitor Cell Markers
• Hematopoietic Stem Cell Markers
• Lymphoid Lineage Markers
• Myeloid Lineage Markers
• Receptor Tyrosine Kinases (RTKs)
• Receptor Tyrosine Kinases (RTKs) in the Akt Pathway
• SCF, Flt-3 Ligand and M-CSF